Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology

Thomas Eschenhagen, Thomas Force, Michael S. Ewer, Gilles W. De Keulenaer, Thomas M. Suter, Stefan D. Anker, Metin Avkiran, Evandro De Azambuja, Jean Luc Balligand, Dirk L. Brutsaert, Gianluigi Condorelli, Arne Hansen, Stephane Heymans, Joseph A Hill, Emilio Hirsch, Denise Hilfiker-Kleiner, Stefan Janssens, Steven De Jong, Gitte Neubauer, Burkert PieskePiotr Ponikowski, Munir Pirmohamed, Mathias Rauchhaus, Douglas Sawyer, Peter H. Sugden, Johann Wojta, Faiez Zannad, Ajay M. Shah

Research output: Contribution to journalArticle

258 Citations (Scopus)

Abstract

The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalEuropean Journal of Heart Failure
Volume13
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Heart Failure
Neoplasms
Morbidity
Therapeutics
Survival
Cardiology
Clinical Trials
Education
Mortality
Growth
Pharmaceutical Preparations

Keywords

  • Anthracyclines
  • Cardio-oncology
  • Cardiotoxicity
  • Consensus statement
  • Heart failure
  • Targeted therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular side effects of cancer therapies : A position statement from the Heart Failure Association of the European Society of Cardiology. / Eschenhagen, Thomas; Force, Thomas; Ewer, Michael S.; De Keulenaer, Gilles W.; Suter, Thomas M.; Anker, Stefan D.; Avkiran, Metin; De Azambuja, Evandro; Balligand, Jean Luc; Brutsaert, Dirk L.; Condorelli, Gianluigi; Hansen, Arne; Heymans, Stephane; Hill, Joseph A; Hirsch, Emilio; Hilfiker-Kleiner, Denise; Janssens, Stefan; De Jong, Steven; Neubauer, Gitte; Pieske, Burkert; Ponikowski, Piotr; Pirmohamed, Munir; Rauchhaus, Mathias; Sawyer, Douglas; Sugden, Peter H.; Wojta, Johann; Zannad, Faiez; Shah, Ajay M.

In: European Journal of Heart Failure, Vol. 13, No. 1, 01.2011, p. 1-10.

Research output: Contribution to journalArticle

Eschenhagen, T, Force, T, Ewer, MS, De Keulenaer, GW, Suter, TM, Anker, SD, Avkiran, M, De Azambuja, E, Balligand, JL, Brutsaert, DL, Condorelli, G, Hansen, A, Heymans, S, Hill, JA, Hirsch, E, Hilfiker-Kleiner, D, Janssens, S, De Jong, S, Neubauer, G, Pieske, B, Ponikowski, P, Pirmohamed, M, Rauchhaus, M, Sawyer, D, Sugden, PH, Wojta, J, Zannad, F & Shah, AM 2011, 'Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology', European Journal of Heart Failure, vol. 13, no. 1, pp. 1-10. https://doi.org/10.1093/eurjhf/hfq213
Eschenhagen, Thomas ; Force, Thomas ; Ewer, Michael S. ; De Keulenaer, Gilles W. ; Suter, Thomas M. ; Anker, Stefan D. ; Avkiran, Metin ; De Azambuja, Evandro ; Balligand, Jean Luc ; Brutsaert, Dirk L. ; Condorelli, Gianluigi ; Hansen, Arne ; Heymans, Stephane ; Hill, Joseph A ; Hirsch, Emilio ; Hilfiker-Kleiner, Denise ; Janssens, Stefan ; De Jong, Steven ; Neubauer, Gitte ; Pieske, Burkert ; Ponikowski, Piotr ; Pirmohamed, Munir ; Rauchhaus, Mathias ; Sawyer, Douglas ; Sugden, Peter H. ; Wojta, Johann ; Zannad, Faiez ; Shah, Ajay M. / Cardiovascular side effects of cancer therapies : A position statement from the Heart Failure Association of the European Society of Cardiology. In: European Journal of Heart Failure. 2011 ; Vol. 13, No. 1. pp. 1-10.
@article{19a0c059234c4a6fb6dbbccbac51bf84,
title = "Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology",
abstract = "The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.",
keywords = "Anthracyclines, Cardio-oncology, Cardiotoxicity, Consensus statement, Heart failure, Targeted therapy",
author = "Thomas Eschenhagen and Thomas Force and Ewer, {Michael S.} and {De Keulenaer}, {Gilles W.} and Suter, {Thomas M.} and Anker, {Stefan D.} and Metin Avkiran and {De Azambuja}, Evandro and Balligand, {Jean Luc} and Brutsaert, {Dirk L.} and Gianluigi Condorelli and Arne Hansen and Stephane Heymans and Hill, {Joseph A} and Emilio Hirsch and Denise Hilfiker-Kleiner and Stefan Janssens and {De Jong}, Steven and Gitte Neubauer and Burkert Pieske and Piotr Ponikowski and Munir Pirmohamed and Mathias Rauchhaus and Douglas Sawyer and Sugden, {Peter H.} and Johann Wojta and Faiez Zannad and Shah, {Ajay M.}",
year = "2011",
month = "1",
doi = "10.1093/eurjhf/hfq213",
language = "English (US)",
volume = "13",
pages = "1--10",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Cardiovascular side effects of cancer therapies

T2 - A position statement from the Heart Failure Association of the European Society of Cardiology

AU - Eschenhagen, Thomas

AU - Force, Thomas

AU - Ewer, Michael S.

AU - De Keulenaer, Gilles W.

AU - Suter, Thomas M.

AU - Anker, Stefan D.

AU - Avkiran, Metin

AU - De Azambuja, Evandro

AU - Balligand, Jean Luc

AU - Brutsaert, Dirk L.

AU - Condorelli, Gianluigi

AU - Hansen, Arne

AU - Heymans, Stephane

AU - Hill, Joseph A

AU - Hirsch, Emilio

AU - Hilfiker-Kleiner, Denise

AU - Janssens, Stefan

AU - De Jong, Steven

AU - Neubauer, Gitte

AU - Pieske, Burkert

AU - Ponikowski, Piotr

AU - Pirmohamed, Munir

AU - Rauchhaus, Mathias

AU - Sawyer, Douglas

AU - Sugden, Peter H.

AU - Wojta, Johann

AU - Zannad, Faiez

AU - Shah, Ajay M.

PY - 2011/1

Y1 - 2011/1

N2 - The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.

AB - The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.

KW - Anthracyclines

KW - Cardio-oncology

KW - Cardiotoxicity

KW - Consensus statement

KW - Heart failure

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=78650383580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650383580&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfq213

DO - 10.1093/eurjhf/hfq213

M3 - Article

C2 - 21169385

AN - SCOPUS:78650383580

VL - 13

SP - 1

EP - 10

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 1

ER -